Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Concetta Crivera

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
American Journal of Hematology|June 16, 2018
An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution"Michael B Streiff, Dejan Milentijevic, Keith McCrae, et al.
The EPMA Journal|March 7, 2020
Evaluation of machine learning methodology for the prediction of healthcare resource utilization and healthcare costs in patients with critical limb ischemia-is preventive and personalized approach on the horizon?Jeffrey S Berger, Lloyd Haskell, Windsor Ting, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 21, 2017
External validation of the multivariable 'In-hospital Mortality for PulmonAry embolism using Claims daTa' prediction rule in the Premier Hospital DatabaseElaine Nguyen, William Frank Peacock, Gregory J Fermann, et al.
Journal of Medical Economics|February 23, 2018
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety resultsPhilip S Wells, Anthonie W A Lensing, Lloyd Haskell, et al.
Current Medical Research and Opinion|July 1, 2017
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studiesChristine G Kohn, Gregory J Fermann, W Frank Peacock, et al.
Internal and Emergency Medicine|October 21, 2016
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarinErin R Weeda, Philip S Wells, W Frank Peacock, et al.
International Journal of Cardiology|August 15, 2016
Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxabanErin R Weeda, Philip S Wells, W Frank Peacock, et al.
Clinical Therapeutics|June 25, 2017
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTEAlok A Khorana, Jeffrey S Berger, Philip S Wells, et al.
International Journal of Clinical Practice|January 19, 2017
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation statusErin R Weeda, W Frank Peacock, Gregory J Fermann, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 3, 2016
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?Craig I Coleman, Gregory J Fermann, Erin R Weeda, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
American Journal of Hematology|June 16, 2018
An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution"Michael B Streiff, Dejan Milentijevic, Keith McCrae, et al.
The EPMA Journal|March 7, 2020
Evaluation of machine learning methodology for the prediction of healthcare resource utilization and healthcare costs in patients with critical limb ischemia-is preventive and personalized approach on the horizon?Jeffrey S Berger, Lloyd Haskell, Windsor Ting, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 21, 2017
External validation of the multivariable 'In-hospital Mortality for PulmonAry embolism using Claims daTa' prediction rule in the Premier Hospital DatabaseElaine Nguyen, William Frank Peacock, Gregory J Fermann, et al.
Journal of Medical Economics|February 23, 2018
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety resultsPhilip S Wells, Anthonie W A Lensing, Lloyd Haskell, et al.
Current Medical Research and Opinion|July 1, 2017
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studiesChristine G Kohn, Gregory J Fermann, W Frank Peacock, et al.
Internal and Emergency Medicine|October 21, 2016
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarinErin R Weeda, Philip S Wells, W Frank Peacock, et al.
International Journal of Cardiology|August 15, 2016
Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxabanErin R Weeda, Philip S Wells, W Frank Peacock, et al.
Clinical Therapeutics|June 25, 2017
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTEAlok A Khorana, Jeffrey S Berger, Philip S Wells, et al.
International Journal of Clinical Practice|January 19, 2017
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation statusErin R Weeda, W Frank Peacock, Gregory J Fermann, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 3, 2016
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?Craig I Coleman, Gregory J Fermann, Erin R Weeda, et al.
Pageof 8